The proposed work will leverage our expertise in regulating macrophage phenotype with materials-based approaches and devices for production of engineered cell therapies. The device investigated in this work for improved manufacture of these emerging technologies has been previously demonstrated for engineering of for adoptive T-cell therapies (ATCTs) and is built upon a well-established partnership with MilliporeSigma, who holds the IP for the device design, and functionalized photoresponsive membranes, where Key Senior Personnel A. Kloxin has related IP. This background IP and relationships will enable rapid progress on the proposed work and provide seamless opportunities for translation. Further, new IP will be filed for macrophage therapies, innovative pretreatment strategies, and their scalable production with the proof-of-concept demonstrations that will be obtained with support from this EDH.
Join the National NSF ART Network – Submit the Membership Request Form
